Molecular subtypes of high-grade serous ovarian cancer: the holy grail?

Affiliations

¹ City University of New York School of Public Health, Hunter College, New York, NY (LW); Novartis Institutes for BioMedical Research, Cambridge, MA (MR); Center for Cancer Research, Massachusetts General Hospital, Boston, MA (MB).
² City University of New York School of Public Health, Hunter College, New York, NY (LW); Novartis Institutes for BioMedical Research, Cambridge, MA (MR); Center for Cancer Research, Massachusetts General Hospital, Boston, MA (MB). mbirrer@partners.org.

Editorial

Levi Waldron et al. J Natl Cancer Inst. 2014.

. 2014 Sep 30;106(10):dju297.

doi: 10.1093/jnci/dju297. Print 2014 Oct.

¹ City University of New York School of Public Health, Hunter College, New York, NY (LW); Novartis Institutes for BioMedical Research, Cambridge, MA (MR); Center for Cancer Research, Massachusetts General Hospital, Boston, MA (MB).
² City University of New York School of Public Health, Hunter College, New York, NY (LW); Novartis Institutes for BioMedical Research, Cambridge, MA (MR); Center for Cancer Research, Massachusetts General Hospital, Boston, MA (MB). mbirrer@partners.org.

No abstract available

Comment on

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL. Konecny GE, et al. J Natl Cancer Inst. 2014 Sep 30;106(10):dju249. doi: 10.1093/jnci/dju249. Print 2014 Oct. J Natl Cancer Inst. 2014. PMID: 25269487 Free PMC article.